MCK
FY2026 Q4 · Calendar Q2 2026
McKesson Corporation
McKesson closed fiscal 2026 with 18% adjusted EPS growth and $6.2 billion in operating cash flow, but Q4 revenue of $96.3 billion fell short of the $101.3 billion consensus as the North American Pharmaceutical segment lagged estimates. The stock declined 3.3% on an abnormal basis in the session following the report before recovering 4.2% in subsequent trading. Management reaffirmed FY27 EPS guidance of $43.80-$44.60, signaling continued 12-14% earnings growth driven by oncology platform expansion, specialty pharmaceutical distribution, and AI-driven automation. The pending Medical-Surgical Solutions separation, anchored by Apollo Funds' $1.25 billion minority investment for a 13% stake, represents a significant strategic milestone expected to unlock value. The shift from raised guidance in Q3 to maintained guidance in Q4 suggests management views the current trajectory as on track…
EPS surprise+1.1%
Market move-2.5%
